<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850797</url>
  </required_header>
  <id_info>
    <org_study_id>S-556/2011</org_study_id>
    <nct_id>NCT01850797</nct_id>
  </id_info>
  <brief_title>Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)</brief_title>
  <acronym>RASUNOA</acronym>
  <official_title>Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry of acute stroke under new oral anticoagulants (RASUNOA) is a German multicenter,
      prospective, observational registry performed at about 50 study centers covering about 50.000
      acute ischemic strokes and 6000 acute intracranial hemorrhages per year. Study enrollment
      will be consecutive. The RASUNOA registry study center is the University Medical Center of
      the Principal Investigator (Heidelberg, Germany). The registry will focus on treatment
      decisions and concepts in patients being under treatment with a new oral anticoagulant and
      suffering from acute ischemic or hemorrhagic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of the study is to collect information from a large, prospectively enrolling
      multicentre stroke database regarding the optimal management of ischemic and hemorrhagic
      stroke during anticoagulation with nOAC. Specifically, we aim to obtain critical information
      regarding the epidemiology, natural history, laboratory and neuroradiological aspects,
      clinical consequences, and the effects of treatment (i.e. thrombolysis/interventional
      recanalisation in ischemic stroke and hemostatic therapy in ICH, respectively) in stroke
      during nOAC. The Registry is not limited to a specific new OAC but intends to examine stroke
      during use of any of the approved nOAC. The study is not designed to perform comparisons
      among the different nOAC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hematoma expansion (ICH)</measure>
    <time_frame>48h after ICH</time_frame>
    <description>Rate of hematoma enlargement in patients with ICH between initial imaging and follow-up imaging (CT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic intracerebral haemorrhage after thrombolysis</measure>
    <time_frame>24 h</time_frame>
    <description>In patients with ischemic stroke while under treatment with any of the new OAC who receive thrombolysis we will measure any hemorrhagic transformation on routine follow-up CT imaging (usually within 24h after thrombolysis)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">353</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Intracranial Hemorrhage</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <description>Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from acute ischemic stroke or intracranial hemorrhage while being anti
        coagulated. Only patients taking new oral anticoagulants will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  informed consent

          -  acute stroke or intracranial bleeding

          -  therapy with a new oral anticoagulant (Dabigatran速, Rivaroxaban速, Apixaban速,
             Edoxaban速)

        Exclusion Criteria:

          -  missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Veltkamp, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-heidelberg.de/Schlaganfall-Studien.707.0.html</url>
    <description>RASUNOA - Center Homepage</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>August 15, 2015</last_update_submitted>
  <last_update_submitted_qc>August 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Roland Veltkamp</investigator_full_name>
    <investigator_title>Senior Physician, Department of Neurology, University Hospital Heidelberg</investigator_title>
  </responsible_party>
  <keyword>oral anticoagulants</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>blood thinner</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

